Cargando…
CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
Patients with non-Hodgkin lymphomas (NHLs) resistant to standard therapies have a dismal prognosis. The outcome is even poorer in patients relapsing after autologous stem cell transplantation. Most of these patients do not qualify for an allogeneic hematopoietic cell transplantation (HCT) due to ref...
Autores principales: | Hopfinger, Georg, Jäger, Ulrich, Worel, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746029/ https://www.ncbi.nlm.nih.gov/pubmed/31723824 http://dx.doi.org/10.1097/HS9.0000000000000185 |
Ejemplares similares
-
Personalized cardiac regeneration by stem cells–Hype or hope?
por: Becher, Ulrich Marc, et al.
Publicado: (2011) -
Chimeric antigen receptor T‑cell therapy—a hematological success story
por: Wohlfarth, Philipp, et al.
Publicado: (2018) -
Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021) -
Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
por: Cosso, Federica, et al.
Publicado: (2023) -
Stem cell therapy – Hype or hope? A review
por: Nadig, Roopa R
Publicado: (2009)